AI Breakthrough Revolutionizing NSCLC Treatment with Immunotherapy
Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal…
Continue Reading